Clear All
727 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9317 Sacituzumab govitecan-hziy Trodelvy 2.5mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Jan 1, 2021 In Use
Q5116 Trastuzumab-qyyp Trazimera 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Oct 1, 2019 In Use
J9316 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf Phesgo 10mg Immunotherapy Monoclonal Antibody HER2 No 2020 Jan 1, 2021 In Use
Q5122 Pegfilgrastim-apgf Nyvepria 0.5mg Ancillary Therapy Immunostimulant Granulocyte Colony Stimulating Factor No 2020 Jan 1, 2021 In Use
NA Tazemetostat Tazverik 200mg Chemotherapy Enzyme Inhibitor EZH2 Yes 2020 In Use
NA Avapritinib Ayvakit 200mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Cedazuridine and Decitabine Inqovi 100mg, 35mg Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Yes 2020 In Use
C9066 Sacituzumab govitecan-hziy Trodelvy 10mg Immunotherapy Drug Antibody Conjugate Trop-2 No 2020 Oct 1, 2020 Jan 1, 2021 In Use
J9037 Belantamab mafodontin-blmf Blenrep 0.5mg Immunotherapy Drug Antibody Conjugate BCMA No 2020 Apr 1, 2021 In Use
J9318 Romidepsin, non-lyophilized Romidepsin 0.1mg Chemotherapy Enzyme Inhibitor HDAC No 2020 Sep 27, 2021 In Use
J9073 Cyclophosphamide (ingenus) Cyclophosphamide (ingenus) 5mg Chemotherapy Alkylating Agent Nitrogen Mustard No 2020 Apr 17, 2024 In Use
NA Avapritinib Ayvakit 100mg Chemotherapy Tyrosine Kinase Inhibitor PDGFR, KIT, CSFR1 Yes 2020 In Use
NA Pralsetinib Gavreto 100mg Chemotherapy Enzyme Inhibitor RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 Yes 2020 In Use
J9223 Lurbinectedin Zepzelca 0.1mg Chemotherapy Alkylating Agent Adduct Forming Agent No 2020 Jan 1, 2021 In Use
C9065 Romidepsin Romidepsin 1mg Chemotherapy Enzyme Inhibetor HDAC No 2020 Jan 1, 2021 Sep 27, 2021 No Longer Used
C9062 Daratumumab Hyaluronidase Darzalex Faspro 10mg Immunotherapy Monoclonal Antibody CD38 No 2020 Oct 1, 2020 Jan 1, 2021 No Longer Used
NA Ripretinib Qinlock 50mg Chemotherapy Tyrosine Kinase Inhibitor KIT, PDGFRA Yes 2020 In Use
J9044 Bortezomib Bortezomib 0.1mg Chemotherapy Proteasome Inhibitor 26S No 2019 Nov 3, 2019 Dec 21, 2022 In Use
NA Selinexor Xpovio 20mg, 40mg, 50mg, 60mg Chemotherapy Enzyme Inhibitor XPO1 Yes 2019 In Use
NA Zanubrutinib Brukinsa 80mg Chemotherapy Tyrosine Kinase Inhibitor BTK Yes 2019 In Use
Q5118 Bevacizumab-bvzr Zirabev 10mg Immunotherapy Monoclonal Antibody VEGFR No 2019 Oct 1, 2019 In Use
Q5117 Trastuzumab-anns Kanjinti 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Oct 1, 2019 In Use
NA Entrectinib Rozlytrek 100mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor TRKA, TRKB, TRKC, ROS1, ALK Yes 2019 In Use
J9177 Enfortumab vedotin-ejfv Padcev 0.25mg Immunotherapy Drug Antibody Conjugate Nectin-4 No 2019 Jul 1, 2020 In Use
NA Erdafitinib Balversa 3mg, 4mg, 5mg Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3, FGFR4 Yes 2019 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.